With early detection of prostate cancer recognised as a critical part in reducing the disease’s mortality rate, PanGIA ...

Johnson & Johnson has reported data from a Phase I trial of pasritamig for metastatic castration-resistant prostate cancer ...

Scientists say they have worked out a machine learning method with the ability to provide close to precise survival estimates of patients afflicted ...

Former President Joe Biden has been diagnosed with an "aggressive" form of prostate ... in survival rates highlights a ...

A multiomic approach for detecting clinically significant prostate cancer in seminal fluid: Results from a large multicenter clinical study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

Discover a study that also highlighted that treatment intensification with enzalutamide benefited patients regardless of ...

New research reveals prostate cancer survivors face a significant long-term risk of developing a third primary cancer, with a ...

Dr. Cheryl Matter shares expert insights into the role physician education can play in ensuring innovative tools reach patients and help improve patient care.

Astellas and Pfizer's Xtandi plus ADT showed a decrease in mortality risk in a metastatic hormone-sensitive prostate cancer ...

In this pilot trial, acupuncture produced greater reductions in nocturia (waking up 1 or more times to urinate) relative to ...

Prostate cancer is the fourth most common cancer among men in India. Often symptomless in its early stages, it is highly ...

177Lu-PSMA-617 consolidation therapy post docetaxel in patients with de-novo high-volume metastatic hormone-sensitive prostate cancer: A randomized, phase 2 trial. Outcomes of initial vs delayed ...